Get the Stockscreener App
26.00
1.33%
0.34
Viking Therapeutics Inc stock is traded at $26.00, with a volume of 10.49M.
It is up +1.33% in the last 24 hours and down -19.00% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$25.66
Open:
$25.38
24h Volume:
10.49M
Relative Volume:
2.18
Market Cap:
$2.92B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-27.96
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-35.05%
1M Performance:
-19.00%
6M Performance:
-23.69%
1Y Performance:
-59.60%
1-Day Range:
$24.96
$26.65
1-Week Range:
$23.21
$42.23
52-Week Range:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
26.00 | 4.73B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics Stock: Panic Creates Opportunity (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics' VK2735: Can a Dual-Acting Obesity Pill Navigate Tolerability and Competition to Win the Market? - AInvest
Viking Therapeutics' VK2735 Trial: A Cautionary Tale for Small Biotechs in the Obesity Drug Gold Rush - AInvest
Viking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout Rate - MSN
Here's Why Viking Therapeutics Bounced Back Today - Yahoo Finance
Viking Therapeutics' VK2735: A Game-Changer in Oral Weight Management - AInvest
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny - FinancialContent
Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study - Yahoo Finance
Viking Therapeutics Reports 6 Percent Weight Loss in Phase 1 Trial of Oral Drug VK2735 - geneonline.com
Viking Therapeutics: What's Happening With VKTX Stock? - Forbes
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance
How to Navigate Viking Therapeutics After Disappointing Data - TheStreet Pro
Is Viking Therapeutics A High-Risk High-Reward Biotech Play? - Trefis
Viking Therapeutics shorts gain $0.5B amid selloff: report - MSN
Viking Therapeutics stock maintains Strong Buy rating at Raymond James - Investing.com
Viking Therapeutics short sellers reap $521 million profit in one day amid selloff. - AInvest
Viking Therapeutics shorts gain $0.5B on selloff (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics shares tumble after obesity drug trial disappoints - Proactive financial news
Viking Therapeutics' weight-loss pill disappoints in phase 2 - medwatch.com
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug? - Benzinga
Viking Therapeutics Rises as Phase 3 Trials and Oral Formulation Progress Accelerate - MSN
Viking Therapeutics Plunges 37% on Obesity Drug Trial Concerns - MSN
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns - FinancialContent
Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data - MSN
Oral weight loss drug "crash"! Viking Therapeutics' stock price plummeted 42%, and short sellers made a profit of $521 million overnight. - 富途牛牛
Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone’ - Invezz
Viking Therapeutics Plunges 42.12% on $1.64 Billion Volume, Ranking 39th Despite Strong Trial Data Skepticism - AInvest
Viking Therapeutics Stock Plummets 42% on Clinical Trial Setback - AInvest
Viking Therapeutics Stock Plummets 42% on Weight Loss Drug Setback - AInvest
Viking Therapeutics (VKTX) Sees Record Stock Drop Amid Drug Trial Concerns - GuruFocus
Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell (VKTX) - Seeking Alpha
Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate - Yahoo Finance
Viking Therapeutics Shares Plunge Nearly 50% After Obesity Drug Trial Shows High Discontinuation Rates - geneonline.com
Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More Movers - Barron's
Viking Therapeutics shares rise 1.52% after-hours as obesity pill shows promising weight loss results in Phase 2 trial. - AInvest
Stock Market Today: Home Depot, Intel, and Viking Therapeutics are on the move - TheStreet
Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill - Investor's Business Daily
Viking Therapeutics stock plunges: Weight-loss pill trial disappoints - Yahoo Finance
Stock Movers: Intel, Viking Therapeutics, Home Depot - Bloomberg.com
Viking Therapeutics stock rises as Truist reiterates Buy on weight loss data By Investing.com - Investing.com South Africa
Viking Therapeutics Crashes Over 40% After Weight-Loss Drug Trial Sparks Safety Concerns - International Business Times UK
Viking Therapeutics weakness ‘overdone,’ says Leerink - TipRanks
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme' - Benzinga
Viking Therapeutics stock rating reiterated as Buy by Jefferies - Investing.com
Viking Therapeutics oral weight loss drug hits mark in mid-stage trial but disappoints investors - statnews.com
How does Viking’s oral obesity drug stand up to those of Eli Lilly and Novo? - Seeking Alpha
Viking Therapeutics Shorts Reap $514 Million as Stock Falls 40% - Bloomberg.com
Viking Therapeutics Shares Sink After Obesity Pill Data; Truist Says Sell-Off Overdone - MarketScreener
Viking Therapeutics’ VK2735: Promising Phase 2 Results Highlight Strong Market Potential and Commercial Viability - TipRanks
Stifel says buy Viking Therapeutics following ‘overreaction’ to Phase 2 outcome - TipRanks
Viking Therapeutics stock falls as market weighs Phase 2 weight loss data - Investing.com
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viking Therapeutics Inc Stock (VKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 03 '25 |
Sale |
27.76 |
4,266 |
118,428 |
168,660 |
| Mancini Marianna | Chief Operating Officer |
Jul 03 '25 |
Sale |
27.77 |
4,266 |
118,473 |
377,535 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):